Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update

GlobeNewswire March 19, 2018

aTyr Pharma, Inc. to Host Earnings Call

Accesswire March 19, 2018

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Benzinga.com  March 16, 2018

aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018

GlobeNewswire March 7, 2018

aTyr Pharma to Present at Two Upcoming Investor Conferences in March

GlobeNewswire March 1, 2018

aTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2018

aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium    

GlobeNewswire December 21, 2017

aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference

GlobeNewswire December 7, 2017

aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)

GlobeNewswire November 27, 2017

aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference

GlobeNewswire November 21, 2017

aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

GlobeNewswire November 14, 2017

aTyr Pharma Announces Leadership Transition

GlobeNewswire November 1, 2017

aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society

GlobeNewswire September 27, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  September 7, 2017

aTyr Pharma to Present at Two Upcoming Investor Conferences in September

GlobeNewswire September 5, 2017

aTyr Pharma Announces $45 Million Equity Financing

GlobeNewswire August 28, 2017

aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline

GlobeNewswire August 14, 2017

BioTelemetry, Inc. Completes LifeWatch AG Acquisition

GlobeNewswire July 12, 2017

BioTelemetry, Inc. Reaches a Final Milestone in Acquisition of LifeWatch AG

GlobeNewswire July 7, 2017

LifeWatch: Five-year Corporate Integrity Agreement Success - Fully Completed

PR Newswire Europe Non Regulatory June 9, 2017